{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:52:18Z","timestamp":1759539138001,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.arbres.2019.04.008","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T15:55:44Z","timestamp":1558540544000},"page":"139-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cribado de la tuberculosis latente y terapia biol\u00f3gica"],"prefix":"10.1016","volume":"56","author":[{"given":"Maria Luiza","family":"de Souza-Galv\u00e3o","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Angeles","family":"Jim\u00e9nez-Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2019.04.008_bib0085","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2019.04.008_bib0090","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthiritis Rheum."},{"key":"10.1016\/j.arbres.2019.04.008_bib0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumor necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.arbres.2019.04.008_bib0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/1756-185X.12970","article-title":"Comparison of the risk of infections in different anti-TNF agents: A meta-analysis","volume":"20","author":"Liao","year":"2017","journal-title":"Int J Rheum Dis."},{"key":"10.1016\/j.arbres.2019.04.008_bib0105","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.autrev.2008.07.011","article-title":"Screening for tuberculosis infection prior to initiation of anti-TNF therapy","volume":"8","author":"Lalvani","year":"2008","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.arbres.2019.04.008_bib0110","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.arbres.2019.04.008_bib0115","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/thoraxjnl-2013-203436","article-title":"Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-\u03b1 antagonist therapy","volume":"68","author":"Singanayagam","year":"2013","journal-title":"Thorax"},{"doi-asserted-by":"crossref","unstructured":"Baddley JW, Cantini F, Goletti D, G\u00f3mez-Reino JJ, Mylonakis E, San-Juan R, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH). Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Soluble immune effector molecules [I]: Anti-tumor necrosis factor-\u03b1 agents). J Clin Microbiol Infect. 2018;24 Suppl 2:S10-S20.","key":"10.1016\/j.arbres.2019.04.008_bib0120","DOI":"10.1016\/j.cmi.2017.12.025"},{"key":"10.1016\/j.arbres.2019.04.008_bib0125","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J."},{"doi-asserted-by":"crossref","unstructured":"British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60:800-5.","key":"10.1016\/j.arbres.2019.04.008_bib0130","DOI":"10.1136\/thx.2005.046797"},{"key":"10.1016\/j.arbres.2019.04.008_bib0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1157\/13083915","article-title":"Recommendations on tuberculosis and treatment of inflammatory bowel disease with infliximab. 2006 update","volume":"29","author":"L\u00f3pez-San Rom\u00e1n","year":"2006","journal-title":"Gastroenterol Hepatol."},{"issue":"Suppl 4","key":"10.1016\/j.arbres.2019.04.008_bib0140","doi-asserted-by":"crossref","first-page":"iv2","DOI":"10.1136\/ard.2005.044941","article-title":"Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005","volume":"64","author":"Furst","year":"2005","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.arbres.2019.04.008_bib0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.arbres.2015.04.016","article-title":"Documento de consenso sobre la prevenci\u00f3n y el tratamiento de la tuberculosis en pacientes candidatos a tratamiento biol\u00f3gico","volume":"52","author":"Mir Viladrich","year":"2016","journal-title":"Arch Bronconeumol."},{"key":"10.1016\/j.arbres.2019.04.008_bib0150","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1164\/rccm.201209-1621CI","article-title":"Interferon gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults","volume":"188","author":"Redelman-Sidi","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"unstructured":"World Health Organization. Latent tuberculosis infection: Updated and consolidated guidelines for programmatic management. Geneva. Licence: CC BY-NC-SA 3.0 IGO. [consultado 18 Ene 2019]. Disponible en: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/260233\/9789241550239-%20eng.pdf;jsessionid=6B928ACA73A371B7A1B50E86ADF1ACB1?sequence=1","key":"10.1016\/j.arbres.2019.04.008_bib0155"},{"key":"10.1016\/j.arbres.2019.04.008_bib0160","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.arbres.2018.04.004","article-title":"\u00bfC\u00f3mo realizamos el cribado de infecci\u00f3n tuberculosa latente en pacientes candidatos a terapias biol\u00f3gicas en Espa\u00f1a? Una encuesta multidisciplinar","volume":"54","author":"Quir\u00f3s","year":"2018","journal-title":"Arch Bronconeumol."}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289619302315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289619302315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:38:05Z","timestamp":1759531085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289619302315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0300289619302315"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2019.04.008","relation":{},"ISSN":["0300-2896"],"issn-type":[{"type":"print","value":"0300-2896"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cribado de la tuberculosis latente y terapia biol\u00f3gica","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2019.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}